Venous thromboembolism in Multiple Myeloma patients; a retrospective analysis of 263 myeloma patients.

Snetselaar, L. (Lieve) (2013) Venous thromboembolism in Multiple Myeloma patients; a retrospective analysis of 263 myeloma patients. thesis, Medicine.

Text SnetselaarL.pdf Restricted to Registered users only Download (636kB)

Abstract

Multiple myeloma is a malignant disease characterized by proliferation of B-cells and is especially seen in elderly patients. Since the use of new treatment agencies, such as Immunomodulatory drugs, it became evident that patients diagnosed with Multiple Myeloma had a high chance of developing VTE. Nowadays the use of thromboprophylactic measurements is standard in myeloma patients but there are still many uncertainties about VTE incidence. Studies investigating the use of thromboprophylaxis and VTE incidence have mainly been focussing on patients using Immunomodulatory drugs and studies investigating other forms of treatment are lacking. Besides studies investigating prophylaxis, studies investigating risk factors have not been performed either. We performed a retrospectively analysis of the myeloma patients seen in the University Medical Centre Groningen, investigating VTE incidence and factors which may influence VTE incidence. The general and disease related factors we analysed included age, sex, stage, type of myeloma and height of M-protein. The risk factors we analysed included Diabetes Mellitus, Cardiovascular disease, obesity, Chronic Renal Failure, hypertension, hypercholesterolemia, prior malignancy, history of VTE, history of arterial events, familial thrombosis and coagulopathies. Besides risk factors we also looked at treatment regimens and prophylactic measurements. In total 247 patients were included in this study from which 47 patients developed VTE, making the VTE incidence found 19.1%. When looking at risk factors we found patients with an IgM type myeloma having a significant higher chance of developing thrombosis. We also found patients diagnosed with Diabetes Mellitus having a significant lower risk of developing VTE. When looking at treatment regimens and prophylactic measurement we found no significant differences. Though this study provides new insides in factors contributing to VTE incidence in myeloma patients we recommend further studies investigating these factors since we had a relatively small cohort. Further we recommend future studies investigation VTE incidence in relation treatment regimens other than Immunomodulatory drugs.

Item Type:	Thesis (Thesis)
Supervisor name:	Meijer, Drs. K. and Waal, Drs. E.G.M. De
Faculty:	Medical Sciences
Date Deposited:	25 Jun 2020 10:55
Last Modified:	25 Jun 2020 10:55
URI:	https://umcg.studenttheses.ub.rug.nl/id/eprint/1577

Actions (login required)

View Item